

ArtecMed[®] Green Spring
SARS-CoV-2 Antigen Rapid Test Kit
(Colloidal Gold)

About Us

ARTEC Group has over 20 years of history. Based in Hong Kong, the business has expanded to 19 subsidiaries in response to different areas and established offices in 7 countries around the world. ARTEC has been committed to utilizing technology to improve human life from cosmetics to medical supplies industry. ArtecMed is an ARTEC brand dedicated to medical development.

Artenano in the ARTEC Group has been engaged in nanotechnology and environmental technology research since 2005. Nanostructures have provided particles and material new chemical and physical properties, allowing existing raw materials to breakthrough for new applications.

Artenano has established a laboratory in Hong Kong, which is committed to researching nano-precious metals and nano catalyst technology and applying it to the development of personal use products. The collaboration between Artenano and the Hong Kong Science Park has contributed to the development of local technology through research projects with universities. It also received interviews and reports from multiple medias.

ArtecMed applies Artenano's nanotechnology to improve the quality of human life, providing expertise and products in scientific analysis, antibacterial, indoor air and UV protection. We strive to bring everyone a safe and healthy life with technology.



Our PRODUCTS

**ArtecMed® Green Spring SARS-CoV-2 Antigen Rapid
Test Kit (Colloidal Gold)**

ANTI-EPIDEMIC SERIES

ANTI-EPIDEMIC SERIES

ETHANOL SANITIZERS

CHG SANITIZERS



We do our best for **you and your health**

ArtecMed® Green Spring SARS-CoV-2 Antigen Rapid Test Kit
(Colloidal Gold)

Utilizing Lateral Flow Immunoassay and Colloidal Gold technology to effectively, speedily and accurately detect SARS-CoV-2 antigens of novel coronavirus variants. Available for self-testing at home, the Test Kits let you or your family know your health status promptly and take immediate action to terminate widespread of CoVID-19.

ArtecMed® Green Spring SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold)

CE-certified : European Centre for Disease Prevention and Control (ECDC) data confirms that the sensitivity of the Test Kit is higher than that of similar products¹

WHO-recommended : Sensitivity and Specificity of the Test Kit achieves far beyond World Health Organization (WHO) Recommendation²

Excellent Sensitivity : Clinically proven sensitivity of 96.77%*

Extreme Specificity : Clinically proven specificity of 100%**

* Sensitivity - the sensitivity of a screening test is to identify positive results from individuals with infection. Tests with low sensitivity will result in more false-negatives, which means missed diagnosis for infected people causing false sense of security. ³

** Specificity - the specificity of a screening test is its ability to identify negative results from individuals without infection. Tests with low specificity will result in more false-positives, causing unnecessary anxiety for non-infected people.

Reference:

1. Scheiblauber H, Filomena A, Nitsche A, Puyskens A, Corman VM, Drosten C, Zwirgmaier K, Lange C, Emmerich P, Müller M, Knauer O, Nübling CM. Comparative sensitivity evaluation for 122 CE-marked rapid diagnostic tests for SARS-CoV-2 antigen, Germany, September 2020 to April 2021. Euro Surveill. 2021 Nov;26(44):2100441.
2. World Health Organization. (2021). Antigen-detection in the diagnosis of SARS-CoV-2 infection:interim guidance, 6 October 2021. World Health Organization. <https://apps.who.int/iris/handle/10665/345948>. License: CC BY-NC-SA 3.0 IGO.
3. Performance of Rapid Antigen Test for Coronavirus Disease 2019 (COVID-19), Department of Health, The Government of Hong Kong SAR <https://www.mdd.gov.hk/filemanager/common/mdacs/RAT-pamphlet-EN.pdf>



ArtecMed® Green Spring SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold)

Rapid Analysis : Result available in 15 minutes

Simple Steps : 4 simple steps involved. Applicable for nasal-pharynx / anterior nasal / pharynx / saliva sampling

Variants Detection : Effectively detect variants of the novel coronavirus, including Alpha, Beta, **Delta**, Epsilon, Zeta and **Omicron**, etc.

Individual Packaging : Each box contains 10 individual Test Kits

Global Bestsellers : Bestsellers in UK, Germany, Belgium and Spain



Cq Value and Virus

Cq value (cycle threshold) is an indicator of the patient's virus content and its infectivity. The higher the Cq value, the lower the viral load of a patient is, and more sophisticated instrument is required for detection.

Virus content carried by the patient was limited just after infection. It contributes a higher Cq value and lower risk transmission.

ArtecMed® Green Spring SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold) achieves high sensitivity even in high Cq value cases.


Choose ArtecMed® Green Spring SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold) for a rapid test to avoid the widespread of the novel coronavirus to **your loved ones** as soon as possible.

Reference:

1. Scheiblaue H, Filomena A, Nitsche A, Puyskens A, Corman VM, Drosten C, Zwirgmaier K, Lange C, Emmerich P, Müller M, Knauer O, Nübling CM. Comparative sensitivity evaluation for 122 CE-marked rapid diagnostic tests for SARS-CoV-2 antigen, Germany, September 2020 to April 2021. Euro Surveill. 2021 Nov;26(44):2100441.



Sterile swab



Extraction tube with buffer

Name	Box Set	Size	Outer size (L*W*H/cm)	Weight (Kg)
ArtecMed® Green Spring SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold)	10 tests/box	21.5*13.5*7.5 inner box 21*7*1.3	70.3*44.9*32 .4	15.5

Table 1: Clinical Study (nasopharyngeal)

ArtecMed Green Spring SARS CoV-2 Antigen Rapid Test Kit (Colloidal Gold)	PCR-Comparator		Total
	Positive	Negative	
Positive	150	0	150
Negative	5	210	215
Total	155	210	365
Sensitivity	96,77% (95%CI: 92,24-98,81%)		
Specificity	100,00% (95%CI: 97,76-100%)		
Accuracy	98,63% (95%CI: 96,89-100%)		

PPA(Ct < 37): 96,77% (150/155), (95%CI: 92,24-98,81%)

NPA(Ct < 37): 100,00% (21&210), (95%CI: 97,76-100%)

www.artecMed.com.hk



Product Details

Comparative evaluation results of SARS-CoV-2 antigen rapid diagnostic tests passing the sensitivity criteria

TABLE 1A
Comparative evaluation results of SARS-CoV-2 antigen rapid diagnostic tests passing the sensitivity criteria (sorted by performance in the subgroup of the evaluation panel, Germany, 2022–2023 (n = 96))

ID#	Manufacturer	Test name	Sensitivity			
			Cq ≤ 25	Cq >25 – <30	Cq ≥ 30	Cq 17–36
Test name			Sensitivity			
100% for Cq ≤ 25 and of >75% for Cq >25– <30						
Technology	Green Spring SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold)		100.0%	95.7%	40.0%	86.0%
85	Tibotec International (Bioscience) GmbH Co., Ltd.	SARS-CoV-2 Antigen Rapid Test ER	100.0%	87.0%	20.0%	78.0%
86	Zhejiang Orient Gene Biotech Co., Ltd.	Concession Ag Rapid Test Cassette (Swab)	100.0%	87.0%	0.0%	76.0%
87	Siemens Healthineers	CLINITEST Rapid COVID-19 Antigen Test	100.0%	87.0%	0.0%	76.0%
88	Geniee Biotech, Inc.	One Step Test for SARS-CoV-2 Antigen (Colloidal Gold)	100.0%	83.0%	0.0%	73.0%
89	Merlin Biomedical (Element) Co., Ltd.	SARS-CoV-2 Antigen Rapid Test Cassette	100.0%	82.0%	0.0%	72.0%
90	BioRapart GmbH	Covid-19 Antigen Schnelltest	100.0%	78.0%	0.0%	70.0%
91	Amadeo Laboragnostik GmbH	AMP Rapid Test SARS-CoV-2 Ag	100.0%	78.0%	0.0%	70.0%
92	BIOINTEK SWISS SA	BIOINTEK COVID-19 Ag BSS	100.0%	78.0%	11.0%	70.0%
93	Hangzhou Lysan Biotechnology Co., Ltd.	Lysan COVID-19 Antigen Rapid Test Device (Colloidal Gold)	100.0%	78.0%	0.0%	70.0%
94	Hangzhou Diagnostic Biotechnology Co., Ltd.	COVID-19 Antigen Rapid Test Cassette (Colloidal Gold)	100.0%	78.0%	0.0%	68.0%
95	Mental Health Works Biological Pharmacy Enterprise Co., Ltd.	SARS-CoV-2 Ag Rapid Test (FM)	100.0%	78.0%	0.0%	70.0%
Subgroup of RDT with detection rates of 100% for Cq ≤ 25 and of >75% for Cq >25 – <30						
96	Supertech, Inc.	SOI-Rex COVID-19 Ag	100.0%	75.0%	0.0%	68.0%
97	Wuhan East-Genomics Biomedical Co., Ltd.	COVID-19 (SARS-CoV-2) Antigen Test Kit	100.0%	75.0%	0.0%	68.0%
98	ASAN PHARM CO., LTD.	Asan Easy Test COVID-19 Ag	100.0%	69.0%	0.0%	66.0%
99	Lumigenix (Quidel) Co., Ltd.	PocStar SARS-CoV-2 Antigen Schnelltest Set (Nasopharyngeal)	100.0%	65.0%	0.0%	64.0%
100	SD BIOSENSORS	STANDARD F COVID-19 Ag FM	100.0%	65.0%	0.0%	64.0%
101	BKNDI®	NowCheck COVID-19 Ag Test	100.0%	65.0%	0.0%	64.0%
102	BIONOTE	NowCheck COVID-19 Ag Test	100.0%	65.0%	0.0%	64.0%
103	Abbott Rapid Diagnostics Jena GmbH	PanbioCOVID-19 Ag Rapid Test Device (NASOPHARYNGEAL)	100.0%	60.9%	0.0%	64.0%
104	Precision Bioscience Inc. (Aeon Laboratory AG)	Enlisa COVID-19 Ag Test	100.0%	60.0%	0.0%	64.0%
105	Saficare Biotech (Hangzhou) Co., Ltd.	Saficare COVID-19 Ag Rapid Test Kit (Swab)	100.0%	60.0%	0.0%	62.0%
106	Shenzhen Walmed Medical Co., Ltd.	SARS-CoV-2 Ag Diagnostic Test Kit (Swab) (Fluorescence)	100.0%	60.0%	0.0%	62.0%

Cq: quantitative cycle; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

Criteria as defined by detection rate of 100% in panel subgroup with Cq ≤ 25.

According to the requirements of the German healthcare system, only rapid antigen detection kits that can achieve a minimum sensitivity of 75% in samples with a Cq value of ≤ 25 are eligible for reimbursement.

ArtecMed® Green Spring SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold) achieves 100% (perfect) sensitivity in samples with Cq value ≤ 25.

The Test Kit achieves an excellent 95.7% sensitivity in samples with Cq value >25 – <30, ranking top in the world.



Product Details

Liste der Antigen-Tests zur professionellen Anwendung zum direkten Erregernachweis des Coronavirus SARS-CoV-2

die Gegenstände des Anspruchs nach § 1 Satz 1 der "Verordnung zum Anspruch auf bestimmte Testungen für den Nachweis des Vorliegens einer Infektion mit dem Coronavirus SARS-CoV-2 (Coronavirus-Testverordnung – TestV)" sind.

Allgemeine Hinweise

Das BfArM stellt hier eine Liste nach § 1 Satz 1 TestV der Antigen-Tests zum direkten Erregernachweis des Coronavirus SARS-CoV-2 bereit, die vom Hersteller zur professionellen Anwendung zweckbestimmt sind („Schnelltests“) und nach Kenntnis des BfArM eine CE-Kennzeichnung tragen.

Das BfArM hat zum 25.08.2021 eine Änderung der Liste dahingehend vorgenommen, dass ab diesem Tag keine Daten zu Vertreibern mehr in der Übersicht aufgeführt werden. Hintergrund ist, dass die Vertriebskanäle entsprechender Tests nach unserer Kenntnis inzwischen gut etabliert sind, Vertrieberlisten einzelner Tests nicht mehr vollständig die Vertriebssituation wiedergeben und es für professionelle Anwender genügend Alternativen für die Ermittlung potentieller Vertrieber eines entsprechenden Antigen Schnelltests gibt.

Änderungen zu bestehenden Listungen oder Neuaufräge zur Aufnahme in die Marktübersicht können nur vom Hersteller des Tests, seinem europäischen Bevollmächtigten oder einem vom Hersteller schriftlich beauftragten Verfahrensbevollmächtigten beantragt werden.

Weitere Hinweise zur vom BfArM bereitgestellten Liste sowie zu den der Sonderzulassung durch das BfArM, Aufnahme in die Liste und ggfs. auch Streichung von der Liste zugrundeliegenden Verfahren und Kriterien finden Sie auf unserer Webseite zu Antigen Tests auf SARS-CoV-2.

Eine Marktübersicht nach § 1 Satz 1 TestV zu Antigen-Tests zum direkten Erregernachweis des Coronavirus SARS-CoV-2, die vom Hersteller zur Eigenanwendung zweckbestimmt sind („Selbsttests“) finden Sie unter diesem Link.

Alle Daten gemäß Übermittlung des Herstellers, verbindlich sind ausschließlich die Angaben in den jeweiligen Gebrauchsinformationen.

Die Angabe „Evaluation PEI“ bildet die entsprechende, auf der Webseite des Paul-Ehrlich-Instituts (PEI) veröffentlichte Übersicht zur dortigen vergleichenden Evaluation der Sensitivität von SARS-CoV-2 Antigen Schnelltests ab (siehe Webseite des PEI).

- „Ja“ bedeutet, dass der Test bereits mit positivem Ergebnis durch das PEI evaluiert wurde.
- „Nein“ bedeutet, dass bislang keine entsprechenden Testergebnisse vorliegen.

Im Falle einer negativen Evaluation durch das PEI streicht das BfArM den entsprechenden CE-gekennzeichneten Test von seiner Liste. Für eine Sonderzulassung ist eine positive Evaluation des PEI eine zwingende Voraussetzung.

Hinweis: Eine aktuelle Übersicht der SARS-CoV-2-Tests, die von den europäischen Mitgliedsstaaten gegenseitig für COVID-19-Testergebnisbescheinigungen anerkannt werden und damit für das „EU Digital COVID-19 Certificate“ berücksichtigt werden können, finden Sie im entsprechenden Dokument der Europäischen Kommission: [Link zum Dokument](#)

Suche: Len Aktionen Zurücksetzen

Nach 'Inhlyuan' suchen

 Nach 'Inhlyuan' suchen

Test-ID	Handelsname	Evaluier... PEI	Name T...	Stadt	Land	Europäischer Bevollmächtigter			Sensitivität		Spezifität	Gebrauch...		
						Name	Stadt	Land	Tests...	%			95%iges Vertrauensintervall	%
AT417/20	Green Spring® SARS-CoV-2-Antigen-Schnelltest-Set	Ja	Shenzhen Inhlyuan Biotechnology Co., Ltd	Shenzhen	CN	Obelis s.a.	Brüssel	BE	POC (ohne Gerät)	98,00	97,12 - 99,98	100,00	98,12 - 99,99	
AT1188/21	Green Spring SARS-CoV-2-Antigen-Schnelltest-Set (bakterielles Gold)	Ja	Shenzhen Inhlyuan Biotechnology Co., Ltd	Shenzhen	CN	Obelis s.a.	Brüssel	BE	POC (ohne Gerät)	96,77	92,24 - 98,81	100,00	97,76 - 99,99	

< 1 > 1 - 2 von 2

letzte Änderung: 30.12.2021 21:19 * POC = Point of Care

BfArM MediGermany BfArM Approval of Green Spring Antigen test for professional use BfArM (German Governmental Authority)cal Infographic

SELF TESTING

Germany BfArM Approval of Green Spring Antigen test for self-testing

The screenshot shows the BfArM website page titled "Antigen-Tests zum direkten Erregernachweis des Coronavirus SARS-CoV-2". The page contains a list of approved antigen tests for self-testing. The first entry is the Green Spring SARS-CoV-2 antigen test, manufactured by Shenzhen Lvshiyuan Biotechnology Co., Ltd. in China. The test is approved for use in Germany and has a sensitivity of 96.80% and a specificity of 96.62%.

Antigen-Tests zum direkten Erregernachweis des Coronavirus SARS-CoV-2

Liste der Antigen-Tests zur Eigenanwendung zum direkten Erregernachweis des Coronavirus SARS-CoV-2.

die Gegenstand des Anspruchs nach § 1 Satz 1 der "Verordnung zum Anspruch auf bestimmte Testungen für den Nachweis des Vorliegens einer Infektion mit dem Coronavirus SARS-CoV-2 (Coronavirus-Testverordnung – TestV)" sind.

Allgemeine Hinweise

Das BfArM stellt hier eine Liste nach § 1 Satz 1 TestV der Antigen-Tests zum direkten Erregernachweis des Coronavirus SARS-CoV-2 bereit, **die vom Hersteller zur Eigenanwendung zweckbestimmt sind („Selbsttests“)** und nach Kenntnis des BfArM eine CE-Kennzeichnung tragen oder deren erstmaliges Inverkehrbringen in Deutschland ohne CE-Kennzeichnung vom BfArM nach § 11 Abs.1 MPG derzeit befristet zugelassen wird („Sonderzulassung des BfArM“).

Die Liste wird kontinuierlich aktualisiert, sobald seitens des BfArM weitere entsprechende Sonderzulassungen erteilt wurden, diese, z.B. durch Ablauf der Befristung der Sonderzulassung oder Abschluss der regulären Konformitätsbewertung und CE-Kennzeichnung, nicht mehr bestehen oder das Verfahren zur Aufnahme CE-gekennzeichneter Tests zur Eigenanwendung in die Liste erfolgreich abgeschlossen wurde.

Eine entsprechende Marktübersicht nach § 1 Satz 1 TestV zu Antigen-Tests zum direkten Erregernachweis des Coronavirus SARS-CoV-2, **die vom Hersteller zur professionellen Anwendung zweckbestimmt sind („Schnelltests“)** finden Sie unter folgendem Link.

Weitere Hinweise zur vom BfArM bereitgestellten Liste sowie zu den der Sonderzulassung durch das BfArM, Aufnahme in die Liste und ggfs. auch Streichung von der Liste zugrundeliegenden Verfahren und Kriterien finden Sie auf unserer Webseite zu Antigentests auf SARS-CoV-2.

Alle Daten gemäß Übermittlung des Herstellers, verbindlich sind ausschließlich die Angaben in den jeweiligen Gebrauchsinformationen.

Die Angabe „Evaluierung PEI“ bildet die entsprechende, auf der Webseite des Paul-Ehrlich-Instituts (PEI) veröffentlichte Übersicht zur dortigen vergleichenden Evaluierung der Sensitivität von SARS-CoV-2 Antigenschnelltests ab (siehe Webseite des PEI).

- „Ja“ bedeutet, dass der Test bereits mit positivem Ergebnis durch das PEI evaluiert wurde.
- „Nein“ bedeutet, dass bislang keine entsprechenden Testergebnisse vorliegen.

Im Falle einer negativen Evaluierung durch das PEI streicht das BfArM den entsprechenden CE-gekennzeichneten Test von seiner Liste. Für eine Sonderzulassung ist eine positive Evaluierung des PEI eine zwingende Voraussetzung.

Suche: lvshiyuan

Test-ID	Name des Tests	Evaluierung PEI	Hersteller		Europäischer Bevollmächtigter		Sensitivität		Spezifität		Gebrauchsan...	
			Name	Land	Name	Land	Probennahme	%	95%iges Vertrauensintervall	%		95%iges Vertrauensintervall
5640-S-474/21	Green Spring® SARS-CoV-2-Antigen-Sch...	Ja	Shenzhen Lvshiyuan Biotechnology Co.,Ltd	CN	Obelis s.a.	BE	nasal	96,80	93,71 - 99,89	100,00	96,62 - 100	Link öffn...

CERTIFICATION

Paul-Ehrlich-Institut Certification

Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel
Federal Institute for Vaccines and Biomedicines

Paul-Ehrlich-Institut 

Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel
Federal Institute for Vaccines and Biomedicines

Paul-Ehrlich-Institut 

Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel
Federal Institute for Vaccines and Biomedicines

Paul-Ehrlich-Institut 

12.02.2021

Last updated: 12.02.2021

Comparative evaluation of the sensitivities of SARS-CoV-2 antigen rapid tests

Aim

Comparison of different antigen rapid tests with using identical sample material

Material

Pools from nasopharyngeal and oropharyngeal swabs.

Dry swabs were included in PBS; moist swabs were already included in the transport media of various compositions. Pools are random mixtures obtained from up to 10 samples of comparable CT values diluted 1:10 in negative samples in PBS. The CT values of a pool were determined by means of different PCR assays, and the putative number of RNA copies calculated with the aid of the INSTAND standards. In the case of the PCRs used, a CT value of 25 corresponds to around 10⁶ RNA copies/mL. 18 samples each were analysed with CT-25, 23 samples with CT between 25 and 30, and 9 samples with CT-30. The replication of the virus in cell culture was determined as a possible correlate for infectiousness as another characteristic of the samples.

Method

The pools were aliquoted, frozen, shipped, and thawed for evaluation of the tests. For each test, 50 µl of the pool were analysed using the components of the test provided, e.g. swabs. Laboratories participating in the comparative evaluation included the Robert Koch-Institut, the Paul-Ehrlich-Institut, the reference laboratory for coronaviruses (Charité), and the Institute for Microbiology of the German Army (Bundeswehr).

Summary

This comparative evaluation of a large number of SARS-CoV-2 rapid antigen tests (point of care tests; POCT) of different designs and manufacturers with the same sample set allows an overview of the current state of art regarding sensitivity. The results do not allow any conclusions regarding specificity of the tests.

Those POCTs which have up to now been included in the evaluation and have been assessed as reflecting the current state of the art are listed in the table below. Other tests, which were assessed as not reflecting the state of the art were deleted from the list of the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM). This comparative evaluation is constantly continued, and the table is amended accordingly.

You should be aware that this comparative evaluation can only cover a random sample of the SARS-CoV-2 rapid antigen tests listed by the BfArM, thus eligible for refunding, and that many other products could not (yet) be taken into account, despite the interests on the part of the manufacturers/distributors.

Contact

Email: sarscov2vid@pei

Overview of SARS-CoV-2 Antigen Rapid Tests Assessed as Reflecting the Current State of the Art

Name of Test	Manufacturer (Distributor)
Panbio™ COVID-19 Ag Rapid Test Device (NASOPHARYNGEAL)	Abbott Rapid Diagnostics Jena GmbH
RDASQUICK SARS-CoV-2 Antigen	R-Biopharm AG
SARS-CoV-2 Rapid Antigen Test	SD BIOSENSOR (Roche Diagnostics GmbH)
NADAL® COVID-19 Ag Schnelltest	nal von minden gmbh
STANDARD™ F COVID-19 Ag FIA	SD BIOSENSOR
STANDARD™ Q COVID-19 Ag Test	SD BIOSENSOR
BIO SYNEX COVID-19 Ag BSS	BIO SYNEX SWISS SA
MEDsan® SARS-CoV-2 Antigen Rapid Test	MEDsan GmbH
TestNOW® - COVID-19 Antigen	Affimedix
NowCheck® COVID-19 Ag Test	BIONOTE
Coronavirus Ag Rapid Test Cassette (Swab)	Zhejiang Orient Gene Biotech Co., Ltd
Sofiga SARS Antigen FIA	Quidel Corporation
COVID-19 Ag Test Kit	Guangdong Wessell Biotech Co., Ltd.
CLINITEST® Rapid COVID-19 Antigen Test	Siemens Healthineers
ESPLINE® SARS-CoV-2	Fujirebio Inc. (Mast Diagnostica GmbH)
BD Veritor™ System for Rapid Detection of SARS-CoV-2	Becton Dickinson
GenBody COVID-19 Ag	IVC Pragen Healthcare
LumiraDx SARS-CoV-2 Ag Test	LumiraDX
Exdia COVID-19-Ag-Test	Precision Biosensor Inc. (Axon Lab AG)
SARS-CoV-2 Ag Rapid Test (FIA)	Wantan (Beijing Wantan Biological Pharmacy Enterprise Co., Ltd.)
SARS-CoV-2 Antigen Schnelltest	Xiamen Boson Biotech Co., Ltd (Medicovid-AG; technomed GmbH; Löwe Medizintechnik)
COVID-19 Antigen Schnelltest (Colloidal Gold)	Joinstar Biomedical Technology Co., Ltd (CIV care impuls Vertrieb)
mö-screen Corona Antigen Test	Molab GmbH
Rapid SARS-CoV-2 Antigen Test Card	MP Biomedicals Germany GmbH
Lyher Novel Coronavirus (COVID-19) Antigen Test Kit (Colloidal Gold)	Hangzhou Laihe Biotech Co., Ltd. (Lissner Qi GmbH)
AMP Rapid Test SARS-CoV-2 Ag	Ameda Labor diagnostik GmbH
Clungene COVID-19 Antigen Rapid Test	Hangzhou Clungene Biotech Co., Ltd.
Gensure™ COVID-19 Antigen Rapid Test Kit	GenSure Biotech Inc.
SARS-CoV-2 Antigen Rapid Test Kit	Beijing Lepu Medical Technology Co., Ltd
HighTop SARS-CoV-2 (Covid-19) Antigen Rapid Test	Qingdao Hightop Biotech Co., Ltd.
Rapid Covid-19 Antigen Test (Colloidal Gold)	Anbio (Xiamen) Biotechnology Co., Ltd

Name of Test	Manufacturer (Distributor)
Safecare COVID-19 Ag Rapid Test Kit (Swab)	Safecare Biotech Hangzhou Co., Ltd.
QuickProfile Covid-19 Antigen Test Card	LumiQuick Diagnostics, Inc.
Covid 19 Antigen Schnelltest	BioRepair GmbH
Green Spring SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold)	Shenzhen Lvshiyuan Biotechnology Co., Ltd.
CAT Antigen Covid Rapid Test	Oncosom Onkoljogk Sislemler San. Ve Tic. A.S.
ScheBo SARS-CoV-2 Quick Antigen	ScheBo Biotech AG
Nova Test SARS-CoV-2 Antigen Rapid Test Kit	Atlas Link Technology Co., Ltd.
Toda Coronadiag Ag	Toda Pharma
Humasit COVID-19 Ag Test	Humasit Co., Ltd.
Beijing Hotgen Biotech Co., Ltd.	Neuartiges Coronavirus (2019-nCoV)-Antigentest (Kolloidales Gold); Novel Coronavirus 2019-nCoV Antigen Test (Colloidal gold)
Xiamen AmonMed Biotechnology Co., Ltd.	COVID-19 Antigen Rapid Test Kit (Colloidal Gold)
Canea COVID-19 Antigen Schnelltest	Core Technology Co., Ltd.
fluorecare COVID-19 SARS-CoV-2 Spike Protein Test Kit (Colloidal Gold Chromatographic Immunoassay)	Shenzhen Microprofi Biotech Co., Ltd
Tetsealabs® Rapid Test Kit COVID-19 Antigen Test Cassette	Hangzhou Tetsealabs Biotechnology Co., Ltd
Lysun COVID-19 Antigen Rapid Test Device (Colloidal Gold)	Hangzhou Lysun Biotechnology Co., Ltd.

CERTIFICATION

CE Certification

| 1 of 1




CERTIFICATE OF IVD NOTIFICATION

Ref No.: BS 0171-2020 **BELGIUM** Date: 19/11/2020
 Order No.: OG 0117-2020

THIS IS TO CERTIFY THAT, ACCORDING TO THE COUNCIL DIRECTIVE 98/79/EC, OBELIS S.A. (O.E.A.R.C.) PERFORMED ALL NOTIFICATION DUTIES AND RESPONSIBILITIES AS THE EUROPEAN AUTHORIZED REPRESENTATIVE (E.A.R.) OF:

NAME: SHENZHEN LVSHIYUAN BIOTECHNOLOGY CO., LTD.
ADDRESS: 101, 201, 301, D BUILDING, NO. 2 INDUSTRIAL AVENUE, BUXIN VILLAGE, BUXIN COMMUNITY, DAPENG SUBDISTRICT OFFICE, DAPENG NEW DISTRICT, SHENZHEN, 518120, CHINA.

AS STIPULATED AND DEMANDED BY THE AFOREMENTIONED DIRECTIVE.

The Manufacturer declares that the IVD devices comply with the Directive including all essential requirements.

The Manufacturer has provided Obelis s.a. (O.E.A.R.C.) with all the appropriate declarations according to the 98/79/EC Directive – article 10 requirements including the EC Declaration of Conformity confirming that his In-Vitro Diagnostic medical devices, as stipulated here above, are fulfilling the applicable requirements of the European Council Directive 98/79/EC.

The notification of the following In-Vitro Diagnostic medical devices has been completed by Obelis s.a. (O.E.A.R.C.) on the 18/11/2020 in compliance with the European Council Directive 98/79/EC - article 10 requirements.

IN-VITRO DIAGNOSTIC MEDICAL DEVICES: PLEASE SEE ANNEX A - LIST OF DEVICES (1 PAGE, 1 DEVICE)

As of the 19/11/2020, and as long as the manufacturer will continue complying with the heretobove mentioned requirements* he therefore:

- Is required to affix the CE marking on these devices;
- Place these devices in the Territory of Belgium and/or the other EEA Member States (excluding territories not in alignment with Decision 2010/227/EU).



Mr. G. Ekayam CEO
Obelis s.a.

Obelis s.a. European Authorized Representative Center is a member of the European Association of Authorized Representatives (E.A.A.R.), ISO 9001 : 2015 and ISO 13485 : 2016 certified in accordance to the profession of a European Authorized Representative.

* This Certificate will be automatically void if the notification is rejected by the EU Authorities or upon termination of the E.A.R. agreement.

Registered Address: St. Général Walle 53-1020 Brussels | Registered Office Address: Bd Brand Whitlock 30, B-1200 Brussels - Belgium




Order No.: OG 0117-2020
 Ref No.: BS 0171-2020

Annex A - List of Devices

(Recital 29 of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices)

#	Catalogue reference number	Commercial Name	Generic Device Term	Short description and intended use	GMDN/EDMS Code	Class
1	GF102B1	SARS-CoV-2 Antigen Rapid Test Kit	SARS-CoV-2 (COVID-19) Antigen Rapid Test Kit (Colloidal Gold)	SARS-CoV-2 (Covid-19) Antigen Rapid Test Kit is used to quantitatively detect antigen of the novel coronavirus in nasal swab.	15.04.80.19	Others





Thank You